|
|
100 S. Main Street, Suite 300
Doylestown, PA 18901 United States
phone:(267) 880-1595
fax:267-880-1596
|
|
| Symbol |
QTXB |
| Exchange |
OTC.BB |
| Founded |
0 |
| Employees |
|
|
|
| www.quantrx.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Products for advanced diagnosis of serious disease and health conditions. |
|
| Management |
| Walter W. Witoshkin, Chairman & Chief Executive Officer; Sasha Afanassiev, Chief Financial Officer & Vice President, Finance; David R. Elmaleh, Chairman & CEO FluoroPharma, Inc; Cindy E. Horton, Vice President, Diagnostics; Michael Hogan, Founder & Chief Scientific Officer Genomics USA; William H. Fleming, Chief Scientific Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| women's health, women's, womenshealth, diagnostics, hemorrhoid |
|
|
|
| Description |
|
QuantRx Biomedical Corporation is an emerging leader in the development of products for advanced diagnosis of serious disease and health conditions. With synergistic expertise in the discovery of diagnostic platforms and the commercialization of products for use by medical professionals, institutions, and consumers, QuantRx is focused on providing more accurate, reliable, and faster diagnoses that result in improved patient care. |
|
| Products / Services |
The company is developing Miniform, a disposable technology with applications in the incontinence and hemorrhoidal over-the-counter markets; Rapid-Sense, a point-of-care diagnostic technology; Miniform PAD technology for various consumer health issues, such as temporary relief of hemorrhoid discomfort, feminine incontinence, drug delivery, and medical sample collection for diagnostic testing; and a collection device for oral fluids.
|
|
| Market / Customers |
The QuantRx strategy is one of sustained growth and targets significant market opportunities estimated to be in excess of $4 billion worldwide.
|
|
| Strategy |
QuantRx is focused on providing more accurate, reliable and faster diagnoses that result in improved patient care.
The QuantRx strategy is one of sustained growth and targets significant market opportunities estimated to be in excess of $4 billion worldwide.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members